IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

WHITTAKER

Title:

METHODS AND

COMPOSITIONS FOR

MEASURING BIOLOGICALLY

ACTIVE NATRIURETIC PEPTIDES AND FOR IMPROVING THEIR

THERAPEUTIC POTENTIAL

Appl. No.:

10/645,874

Filing Date:

August 20, 2003

Examiner:

Lum

Art Unit:

1641

Confirmation 8658

Number:

INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR §1.56**

Mail Stop Amendment-IDS Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits after the filing of a Request for Continued Examination.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicant respectfully requests that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08be returned in accordance with MPEP \$609.

Although Applicant believes that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 19-0741.

Respectfully submitted,

Date 07/24/2007

FOLEY & LARDNER LLP

Customer Number: 30542 Telephone:

(858) 847-6722

Facsimile:

(858) 792-6773

Barry S. Wilson Attorney for Applicant

Registration No. 39.431

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute for for	m 1449/I	PTO	Complete if Known		
	INFORMATION D	DISCLO	SURE	Application Number	10/645,874	
	STATEMENT BY	APPLI	CANT	Filing Date	August 20, 2003	
				First Named Inventor	Whittaker	
				Art Unit	1641	
(use as many sheets as necessary)				Examiner Name	Lum	
Sheet	1	of	2	Attorney Docket Number	071949-7002	

U.S. PATENT DOCUMENTS						
Examiner	Cite	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant	
Initials*	No. ¹	Number-Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear	
	A1	6828107	12-07-2004	Asada et al.	J	
	A2	2005/0181386	08-18-2005	Diamond et al.		
	A3	6117644	09-12-2000	DeBold		
	A4	2005/0244902	11-03-2005	Gotze et al.		

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS							
Examiner Initials*	Cite No. ¹	U.S. Patent Application Document Serial Number-Kind Code ² (if known)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³⁻ Number ⁴⁻ Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶		
	A5	WO 00/052476	09-08-2000	Skye Pharmatech Incorporated		And the second s		

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶				
	A6	Cala, Computerized axial tomography in the detection of brain damage. Medical Journal of Australia, 2(11): 616-620, 1980.					
	A7	Cuzzocrea et al., Effects of tempol, a membrane-permeable radical scavenger, in a gerbil model of brain injury. Brain Research, 875:96-106, 2000.					
	A8	Griffin et al., The inhibition of myeloperoxidase by ceruloplasmin can be reversed by anti-myeloperoxidase antibodies. Kidney International, 55:917-925, 1999.					

Evaminar		D-1-	
Examiner	;	Date	
Cimmonto	į		
Signature	į vardos darbas	Considered	
		Controlation	
			The second secon

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant: 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for for	m 1449/l	PTO	Complete if Known		
	INFORMATION D	ISCLO	SURE	Application Number	10/645,874	
	STATEMENT BY	APPLI	CANT	Filing Date	August 20, 2003	
				First Named Inventor	Whittaker	
				Art Unit	1641	
	(use as many sheet	s as ne	cessary)	Examiner Name	Lum	
Sheet	2	of	2	Attorney Docket Number	071949-7002	

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	- Item (hook magazine journal serial symposium catalog etc.) date page(s) volume-issue numbo				
	A9	Minota et al., Circulating myeloperoxidase and anti-myeloperoxidase antibody in patients with vasculitis. Scand J Rheumatol, 28:94-99, 1999.			
	A10	Montaner et al, Matrix metalloproteinase expression after human cardioembotic strike. Stroke, 32:1759-1766, 2001			
	A11	Stronglin, <u>Laboratory diagnosis of viral infections</u> , <u>sensitivity</u> , <u>specificity</u> , <u>and predictive value of diagnostic tests</u> : <u>Definitions and clinical applications</u> . Lennette et al. eds., New York: Marcel Dekker, Inc., p. 211-219, 1992.	THE RESIDENCE OF THE PERSON OF		
	A12	Tervaert, The value of serial ANCA testing during follow-up studies in patients with ANCA-associated vasculitides: A review. Journal of Nephrology, 9(5): 232-240, 1996.			

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to

This collection of information is required by 97 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.